J&J Drug Combo Shows Promise in Treating Lung Cancer
Johnson & Johnson's Rybrevant became the first medication for a particular subset of non-small cell lung cancer (NSCLC) in 2021.
Source: hngn.com
Page 2 - Johnson Rybrevant News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Johnson Rybrevant. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Johnson Rybrevant Today - Breaking & Trending Today
Before key Tagrisso showdown, J&J notches Rybrevant trial win in large lung cancer area
Johnson & Johnson’s Rybrevant is currently approved for a tiny non-small cell lung cancer (NSCLC) niche. | Johnson & Johnson’s Rybrevant is currently approved…
Source: biztoc.com
Bio Startup Scorpion Partners With Pierre Fabre for Trials of Targeted Lung Cancer Drugs
Pierre Fabre is paying Scorpion Therapeutics $65 million to begin a partnership on clinical development and potential commercialization of two targeted therapies for non-small cell lung cancer. The Scorpion drugs could have safety advantages over approved Johnson & Johnson and Takeda therapies that address the same rare genetic signature.
Source: medcitynews.com
Seagen broadens its scope beyond ADC cancer drugs with deal for preclinical asset
Seagen’s cancer drug research and collaborations have focused on the development of antibody drug conjugates. By licensing rights to a preclinical Lava Therapeutics asset, Seagen gets a shot to develop a different kind of antibody therapy that could compete against approved products from Johnson & Johnson and Takeda Pharmaceutical.
Source: medcitynews.com
